| 1 -0.02 (-1.96%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.3  |
1-year : | 1.38 |
| Resists | First : | 1.11 |
Second : | 1.19 |
| Pivot price | 1.06 |
|||
| Supports | First : | 1 | Second : | 0.83 |
| MAs | MA(5) : | 1.03 |
MA(20) : | 1.07 |
| MA(100) : | 1.56 |
MA(250) : | 2.34 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 4.5 |
D(3) : | 9.7 |
| RSI | RSI(14): 37 |
|||
| 52-week | High : | 5.09 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SNTI ] has closed above bottom band by 7.6%. Bollinger Bands are 74.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.04 - 1.05 | 1.05 - 1.06 |
| Low: | 0.98 - 0.99 | 0.99 - 1 |
| Close: | 0.99 - 1 | 1 - 1.01 |
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
Wed, 14 Jan 2026
Senti Biosciences, Inc. Highlights FDA RMAT Designation for SENTI-202 in Virtual Investor CEO Connect Segment - Quiver Quantitative
Thu, 18 Dec 2025
Senti Biosciences Announces New Employment Inducement Grants - Yahoo Finance
Tue, 09 Dec 2025
Why Is Senti Biosciences Stock (SNTI) Up Today? - TipRanks
Tue, 09 Dec 2025
Senti Bio (Nasdaq: SNTI) gains FDA RMAT for SENTI-202 after 50% ORR in AML trial - Stock Titan
Tue, 09 Dec 2025
Unveiling Senti Biosciences: Shaping the Future of Cancer Therapy? - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 56.7 (%) |
| Held by Institutions | 22.2 (%) |
| Shares Short | 1,020 (K) |
| Shares Short P.Month | 298 (K) |
| EPS | -2.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.31 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -67.8 % |
| Return on Equity (ttm) | -394.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.44 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.35 |
| PEG Ratio | 0 |
| Price to Book value | 3.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|